Malaria Vaccine Becomes First To Achieve WHO-specified 75% E
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Researchers have reported findings from a trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated 77 per cent efficacy over 12 months of follow-up. They hope the vaccine can be approved for use within the next two years, building on the speed and lessons learned through the rapid development of Covid jabs.

The authors report from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. 450 participants, aged 5-17 months, were recruited from the catchment area of Nanoro, covering 24 villages and an approximate population of 65,000 people.

The participants were split into three groups, with the first two groups receiving the R21/Matrix-M (with either a low dose or high dose of the Matrix-M adjuvant) and the third, a rabies vaccine as the control group. Doses were administered from early May 2019 to early August 2019, largely prior to the peak malaria season.

The researchers report a vaccine efficacy of 77% in the higher-dose adjuvant group, and 71% in the lower dose adjuvant group, over 12 months of follow-up, with no serious adverse events related to the vaccine noted. Following these results, the Phase IIb trial was extended with a booster vaccination administered prior to the next malaria season one year later.

The researchers, in collaboration with Serum Institute of India Private Ltd., and Novavax Inc., have now started recruitment for a Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children, aged 5-36 months, across four African countries. Reseachers said: "These new results support our high expectations for the potential of this vaccine, which we believe is the first to reach the WHO's goal of a vaccine for malaria with at least 75% efficacy.

Source:
https://californianewstimes.com/malaria-vaccine-becomes-first-to-achieve-who-specified-75-efficacy-goal/292021/
Dr. T●●●●z H●●●●●●i and 8 others like this5 shares
Like
Comment
Share